First in China! Wanbang Biopharma Perphenazine Tablets Pass Generics Consistency evalssuation_R&D News_R&D News_R&D_Fosun Pharma
  • 尊龙凯时 - 人生就是搏!

    2020-10-10

    First in China! Wanbang Biopharma Perphenazine Tablets Pass Generics Consistency evalssuation

    Recently, Shanghai Zhaohui Pharmaceutical Co., Ltd. ("Zhaohui Pharmaceutical"), a member enterprise of Jiangsu Wanbang Biopharmaceuticals Co., Ltd. ("Wanbang Biopharma"), received the Notice on Approval of Supplementary Drug Application for Perphenazine Tablets (2 mg, 4 mg) (No.: 2020B04654, 2020B04655) from NMPA. The drug is the first of its kind in China to pass the consistency evalssuation of quality and efficacy of generic drugs.



    Perphenazine Tablets is indicated for the treatment of schizophrenia and severe nausea and vomiting. By September 2020, Zhaohui Pharmaceutical has invested a cumulative R&D amount of about RMB 10.6 million (not audited) for the consistency evalssuation at this stage.

    Perphenazine Tablets has successfully passed the generics consistency evalssuation, which will help improve the product's competitiveness, enhance the product's market position and bring new market opportunities.
    上海人生就是博·(中国区)官方网站医药集团